AACR Poster Presentation October 7, 2021
Immunotherapeutic Benefits of the DPX Delivery Platform Featured in Two Poster Presentations at the AACR-NCI-EORTC Conference on Molecular Targets and Cancer Therapeutics
Poster presentations show that:
DPX generates peptide-specific, T cell-based immune responses that are more robust and more persistent than conventional water-based formulations
The dual-targeted immunotherapy DPX-SurMAGE elicits a robust and specific T cell response against two tumor antigens along with a good safety profile in preclinical
models
DARTMOUTH, Nova Scotia & CAMBRIDGE, Mass.--(BUSINESS WIRE)-- IMV Inc. (NASDAQ: IMV; TSX: IMV), a clinical-stage biopharmaceutical company pioneering a novel class of immunotherapies against difficult-to-treat cancers, today announced that the immunotherapeutic capabilities of its DPX delivery platform will be featured in two e-poster presentations at the AACR-NCI-EORTC Virtual International Conference on Molecular Targets and Cancer Therapeutics October 7-10, 2021.
“Collectively, these data demonstrate the versatility and potential of the DPX delivery platform to educate robust, targeted T cell responses to distinct cargo,” said Jeremy Graff, Ph.D., Chief Scientific Officer at IMV. “More specifically, the first presentation provides compelling evidence that the DPX technology triggers a more consistent and persistent immune response than conventional emulsions. The second presentation provides the scientific basis for the clinical pursuit of DPX-SurMAGE, a new IMV asset designed to simultaneously elicit immune responses to the survivin and MAGE-A9 proteins, both of which have been implicated in bladder cancer progression.”
Yves Fradet, M.D., Professor, Department of Surgery at the Faculty of Medicine, Universit Laval in Quebec City commented, “The results obtained with IMV’s dual-targeted DPX- based immunotherapy, DPX-SurMAGE, in preclinical studies are very promising. I believe that patients with bladder cancer will benefit from this treatment while maintaining their quality of life.”